Levi & Korsinsky announces that a class action lawsuit has been
commenced in the United States District Court for the District of
Massachusetts on behalf of investors who purchased Sarepta Therapeutics,
Inc. (“Sarepta” or the “Company”) (Nasdaq:SRPT) common stock between
July 24, 2013 through November 12, 2013.
For more information, click here: http://zlk.9nl.com/sarepta-srpt/.
The complaint alleges that Sarepta issued a series of multiple
statements concerning, among other things: (1) the prospects of the Food
and Drug Administration's ("FDA") acceptance for consideration of a New
Drug Application ("NDA") for eteplirsen based on Sarepta's Phase IIb
study data set, and (2) the significance of that data set. However,
during a meeting on November 12, 2013, the FDA informed Sarepta that its
announced, anticipated NDA filing for eteplirsen was premature. On this
news, Sarepta's stock price fell from its closing price of $36.56 per
share on November 11, 2013 to $13.16 per share on November 12, 2013.
If you suffered a loss in Sarepta you have until March 28, 2014 to
request that the Court appoint you as lead plaintiff. Your ability to
share in any recovery doesn’t require that you serve as a lead
plaintiff. To obtain additional information, contact Joseph E. Levi,
Esq. either via email at jlevi@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/sarepta-srpt/.
Levi & Korsinsky is a national firm with offices in New York, New
Jersey, Connecticut and Washington D.C. The firm’s 26 attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. For more information, please feel
free to contact any of the attorneys listed below. Attorney advertising.
Prior results do not guarantee similar outcomes.
Copyright Business Wire 2014